The U.S. FDA has schedule a meeting of the Anesthetic and Analgesic Drug Products Advisory Committee (AADPAC) for Wednesday, March 18, 2015. The committee will discuss new drug application (NDA) 022225, sugammadex sodium injection, submitted by Organon USA Inc., for the proposed indication of reversal of moderate or deep neuromuscular blockade induced by rocuronium or vecuronium.